Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completes the qualifying clinical study final visit~* In the opinion of the principal investigator (PI), has been generally compliant with study requirements during the qualifying study, or must be considered eligible to enroll in PIPF-012 by the InterMune medical monitor~* Is able to provide informed consent and comply with the requirements of the study~Exclusion Criteria:~* Is pregnant or lactating~* Has known hypersensitivity to any of the components of the study drug~* Starts participation in another interventional clinical trial between the end of participation in the qualifying InterMune clinical trial and entry into PIPF-012~* Receives concomitant and/or excluded medications as defined in the protocol~* Permanently discontinues study drug during the qualifying study for any reason before study completion

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): pirfenidone

Based on this trial design, predict the completion outcome and termination type (if applicable).